<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01295892</url>
  </required_header>
  <id_info>
    <org_study_id>pkvw6k</org_study_id>
    <nct_id>NCT01295892</nct_id>
  </id_info>
  <brief_title>Chronic Effects of Estrogen in Microcirculation</brief_title>
  <official_title>Chronic Effects of Estrogen in Microcirculation and Insulin Resistance in Postmenopausal Obese Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rio de Janeiro State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rio de Janeiro State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the chronic effects of estrogen on microcirculation, inflammatory
      biomarkers, hormonal status, plasma viscosity and biochemical tests in postmenopausal obese
      women after three months of follow-up intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Estrogens exert pleiotropic actions on the cardiovascular system through binding to estrogen
      receptors. Traditionally, estrogen receptors have been recognized as transcription factors
      regulating the expression of target genes, however, numerous studies have revealed rapid
      actions of estrogen in different systems, so-called 'extranuclear actions'. At this level,
      estrogen triggers rapid vasodilatation, exerts anti-inflammatory effects, regulates vascular
      cell growth and migration, and confers protection to cardiomyocytes. Our aims are to
      investigate estrogen´s chronic effects on microcirculation.

      The study will assess the potential benefits of estrogens on: chronic low-grade inflammation,
      metabolic profile, microcirculation and blood rheology. Postmenopausal obese women will be
      randomly submitted to estrogen (transdermal 17-β-estradiol 1mg/day) or placebo therapy during
      three months in a double-blind fashion. At baseline and after intervention, nailfold
      videocapillaroscopy, laser-Doppler flowmetry and venous occlusion plethysmography,
      inflammatory biomarkers, hormonal status, metabolic profile, plasma viscosity and
      anthropometrical measures will be assessed in all subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>functional capillary density by videocapillaroscopy(number of perfused capillaries on the studied skin area)</measure>
    <time_frame>03 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood viscosity(the values are expressed in centipoises)</measure>
    <time_frame>03 months</time_frame>
    <description>evaluate the change in blood viscosity after 3 months of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Postmenopausal Symptoms</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (transdermal gel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg of 17B-estradiol/day (transdermal gel)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estrogen</intervention_name>
    <description>transdermal 17-β-estradiol 1mg/day during three months</description>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>Estrogen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of natural menopause defined by the absence of menses for at least 12 months
             and a serum concentration of FSH &gt; 35 IU/L

          -  BMI between 27 to 34.9 kg/m²

          -  Non-smokers

          -  Not on use of any hormones or supplements for a minimum of 6 months prior to the study

          -  No absolute contraindications to the use of physiological replacement doses of
             estrogen

        Exclusion Criteria:

          -  Renal disease, coronary or peripheral vascular diseases, haematologic or hepatic
             diseases

          -  Diabetes mellitus, glucose intolerance or altered fasting glucose
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>48 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diogo Panazzolo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rio de Janeiro State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratorio de Pesquisas Clinicas e Experimentais em Biologia Vascular</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <last_update_submitted>April 17, 2013</last_update_submitted>
  <last_update_submitted_qc>April 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rio de Janeiro State University</investigator_affiliation>
    <investigator_full_name>Luiz Guilherme Kraemer de Aguiar</investigator_full_name>
    <investigator_title>Chronic Effects of Estrogen in Microcirculation and Insulin Resistance in Postmenopausal Obese Women</investigator_title>
  </responsible_party>
  <keyword>menopause</keyword>
  <keyword>obesity</keyword>
  <keyword>capillary</keyword>
  <keyword>microcirculation</keyword>
  <keyword>estrogen</keyword>
  <keyword>Microvascular Function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

